Does Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam Interact with P Gp Or Bcrp Substrates?
Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and P Gp Or Bcrp Substrates have a moderate drug interaction according to U.S. FDA drug labeling data. P-gp inducers are expected to decrease absorption of TAF, resulting in decreased plasma concentration. The mechanism involves induction of p-glycoprotein activity. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam Class
- Cytochrome P450 3A Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and P Gp Or Bcrp Substrates occurs because induction of p-glycoprotein activity. Clinically, this means p-gp inducers are expected to decrease absorption of taf, resulting in decreased plasma concentration. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and your doctor is considering prescribing P Gp Or Bcrp Substrates (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider